Tokyo, July 14 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062224) titled 'An observational study using proteome analysis in VEGF inhibitor-induced proteinuria' on July 13.
Study Type:
Observational
Primary Sponsor:
Institute - Iwate Medical University
Condition:
Condition - Patients with colorectal cancer who are scheduled to initiate VEGF inhibitor therapy
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The aim of this study is to comprehensively analyze changes in plasma proteins associated with the development of proteinuria in patients treated with vascular endothelial growth factor (VEGF) inhibitors, thereby elucidating the molecular mechanisms involved in the development of proteinuria and identifying potential biomarkers for its early prediction.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
=2+ and UPCR >=1.0)
2) Patients with severe renal impairment (eGFR <30 mL/min/1.73 m2)
3) Patients with severe hepatic impairment (Child-Pugh class C or an equivalent condition)
4) Patients with an active infection or an unstable general condition
5) Patients who are pregnant, breastfeeding, or may be pregnant
6) Patients who are deemed unsuitable for participation in this study by the principal investigator
Target Size - 50
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2026 Year 06 Month 26 Day
Date of IRB - 2026 Year 07 Month 03 Day
Anticipated trial start date - 2026 Year 07 Month 04 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071211
Disclaimer: Curated by HT Syndication.
